利奈唑胺在高龄患者中的疗效与安全性分析-现代护理医学杂志-CSCIED科技核心评价数据库-手机版

利奈唑胺在高龄患者中的疗效与安全性分析

Analysis of efficacy and safety of linezolid in elderly patients

ES评分 0 浏览量：419 下载量：0

DOI	10.12208/j.jmnm.20240153
刊名	现代护理医学杂志 Journal of Modern Nursing MedicineJPCNS
年，卷(期)	2024, 3(4)
作者	师禾颖,朱加艳,周晶*,
作者单位	中国人民解放军联勤保障部队第九二〇医院云南昆明 ;
摘要	分析利奈唑胺在高龄重症肺炎患者中的效果。方法选取本院的80例高龄重症肺炎患者，均2021年10月~2023年10月收治，随机分组，各40例。对照组行常规治疗，观察组联合利奈唑胺治疗，比较治疗效果。结果观察组发生率低于对照组，差异无统计学意义（P＞0.05）；观察组肺功能优于对照组，差异有统计学意义（P<0.05）。结论利奈唑胺在高龄重症肺炎患者中的应用，不会使其发生较多的不良反应，还能够改善患者的肺功能。
Abstract	Objective To analyze the effect of linezolid in elderly patients with severe pneumonia. Methods 80 elderly patients with severe pneumonia were selected from our hospital from October 2021 to October 2023, and were randomly divided into 40 cases each. The control group received routine treatment, the observation group combined with linezolid treatment, and the therapeutic effect was compared. Results The incidence in observation group was lower than that in control group, with no statistical significance (P > 0.05). The lung function of observation group was better than that of control group, and the difference was statistically significant (P < 0.05). Conclusion The application of linezolid in elderly patients with severe pneumonia does not cause more adverse reactions and can improve the lung function of patients.
关键词	利奈唑胺；高龄；重症肺炎
KeyWord	Linezolid; Old age; Severe pneumonia
基金项目
页码	4-6

参考文献
相关文献

[1] He Z, Wu X, Zhang W, et al. Effect of combined treatment with linezolid and ulinastatin on respiratory function and serum inflammatory factors in elderly patients with severe pneumonia
[J]. Tropical Journal of Pharmaceutical Research, 2022, 21(7): 1543-1548.
[2] Kato H, Hagihara M, Asai N, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus
[J]. Journal of global antimicrobial resistance, 2021, 24: 98-105.
[3] Kong D, Liu X, Li X, et al. Mesenchymal stem cells significantly improved treatment effects of Linezolid on severe pneumonia in a rabbit model
[J]. Bioscience Reports, 2019, 39(9): BSR20182455.
[4] Wu W, Li L, Duan S, et al. Clinical effectiveness and reliability of linezolid in the treatment of pulmonary tuberculosis complicated with severe pneumonia: a meta-analysis
[J]. American Journal of Translational Research, 2022, 14(11): 7622.
[5] Warda A E A, Sarhan R M, Al-Fishawy H S, et al. Continuous versus intermittent linezolid infusion for critically ill patients with hospital-acquired and ventilator-associated pneumonia: efficacy and safety challenges
[J]. Pharmaceuticals, 2022, 15(3): 296.
[6] Chen H, Du Y, Xia Q, et al. Role of linezolid combination therapy for serious infections: review of the current evidence
[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2020, 39: 1043-1052.
[7] Warda A E A, Sarhan R M, Al-Fishawy H S, et al. Continuous versus intermittent linezolid infusion for critically ill patients with hospital-acquired and ventilator-associated pneumonia: efficacy and safety challenges
[J]. Pharmaceuticals, 2022, 15(3): 296.
[8] 陈婷,魏海明,王玮. 利奈唑胺葡萄糖联合头孢哌酮钠舒巴坦钠治疗重症肺炎的临床效果
[J]. 临床合理用药,2023,16(29):67-69+73.
[9] 崔华永,裴金盛,向斌,仇正锋. 利奈唑胺联合乙酰半胱氨酸对重症肺炎患者血气指标、炎性因子的影响
[J]. 吉林医学,2023,44(6):1567-1571.
[10] Russo A. Spotlight on new antibiotics for the treatment of pneumonia
[J]. Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine, 2020, 14: 1179548420982786.
[11] 康珍,许承斌,费志永. 双歧杆菌三联活菌联合利奈唑胺治疗对重症肺炎的疗效及对患者血气指标、炎症因子的影响
[J]. 中国药物滥用防治杂志,2023,29(6):1016-1019.
[12] 张文凯,谢建威. 盐酸氨溴索联合利奈唑胺治疗重症肺炎患者对血气指标及炎性指标的影响
[J]. 中华养生保健,2023,41(4):169-172.
[13] 王恒辉. 利奈唑胺治疗肺结核合并重症肺炎的效果及对机体免疫影响
[J]. 江西医药,2022,57(10):1443-1445.
[14] Li Y, Fang Q, Wu Z, et al. Population pharmacokinetics and dosage optimization of linezolid in Chinese older patients
[J]. European Journal of Clinical Pharmacology, 2024: 1-10.
[15] 徐敬敬,王运. 血必净联合利奈唑胺治疗老年重症肺炎的效果及对患者血清炎性因子水平的影响
[J]. 临床医学工程,2022,29(1):19-20.

引用本文

师禾颖,朱加艳,周晶*. 利奈唑胺在高龄患者中的疗效与安全性分析 [J]. 现代护理医学杂志. 2024; 3; (4). 4 - 6.

文献评论

相关学者

相关机构